Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Coherus Oncology, Inc.CHRS · Entity 6276 | Chief Financial Officer | February 01, 2021 | February 03, 2021 |
| SpyGlass Pharma, Inc.SGP · Entity 5034 | Chief Financial Officer | February 05, 2026 | February 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Coherus Oncology, Inc.
Report date February 01, 2021 · Filed February 03, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 61,295 |
Last balance in matching sequence
After 2021-02-01 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2021-02-01 · Exercise / conversion · Acquired 7,402 · Balance 68,697 F2: Includes 52,083 restricted stock units. Row 2 · 2021-02-01 · Sale · Disposed 7,402 · Balance 61,295 F1: The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person. F2: Includes 52,083 restricted stock units. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.05 · Expires 2028-02-01 | Direct | 54,167 |
Reported balance
After 2021-02-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-02-01 · Exercise / conversion · Disposed 7,402 · Balance 54,167 F3: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person.
F2: Includes 52,083 restricted stock units.
F3: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
SpyGlass Pharma, Inc.
Report date February 05, 2026 · Filed February 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-02-05 | Direct | 17,500 |
Reported balance
After 2026-02-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-05 · Grant · Acquired 17,500 · Balance 17,500 F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 5, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NGM BIOPHARMACEUTICALS INC
Report date March 26, 2024 · Filed April 08, 2024
Section 16 reporting ended · disclosed 2024-04-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-04-05 transaction · row 1
1 source rowRow 1 · 2024-04-05 · Other · Disposed 3,038 · Balance 0 F1: Includes 3,000 shares acquired under the Issuer's Employee Stock Purchase Plan on March 26, 2024. F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.77 · Expires 2033-11-30 | Direct | 0 |
Reported balance
After 2024-04-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-04-05 · Disposition to issuer · Disposed 450,000 · Balance 0 F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F3: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 3,000 shares acquired under the Issuer's Employee Stock Purchase Plan on March 26, 2024.
F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price").
F3: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 05, 2026 Filed Feb 9, 2026 16:40 UTC | SpyGlass Pharma, Inc. SGP · Entity 5034 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001427569-26-000008 · form4-02092026_090235.xml · derivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2036-02-05 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 5, 2026. Read SEC document |
| April 05, 2024 Filed Apr 8, 2024 16:14 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Disposition to issuerStock Option (Right to Buy) · Derivative | 450,000 | Not disclosed Strike: $0.77 | Not disclosed |
DisclosureSEC source: 0000950170-24-042611 · ownership.xml · derivative · entry 2 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 450,000 shares Expires 2033-11-30 F2 · derivative.exercise_price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F3 · derivative.exercise_price: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. F2 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F3 · price: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. Read SEC document |
| April 05, 2024 Filed Apr 8, 2024 16:14 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | OtherCommon Stock | 3,038 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-042611 · ownership.xml · nonDerivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes 3,000 shares acquired under the Issuer's Employee Stock Purchase Plan on March 26, 2024. F2 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 16:27 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | GrantStock Option (Right to Buy) · Derivative | 450,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001209191-23-057214 · doc4.xml · derivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2033-11-30 F1 · derivative.exercise_date: The shares subject to the option shall vest over a four-year period commencing November 3, 2023, with 1/4th of the shares vesting on November 3, 2024 and 1/48th of the shares vesting monthly thereafter. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 17:37 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,402 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0001567619-21-002141 · doc1.xml · derivative · entry 3 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,167 Underlying: Common Stock · 7,402 shares Expires 2028-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 17:37 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock | 7,402 | $21.55 | $159,513.10 |
DisclosureSEC source: 0001567619-21-002141 · doc1.xml · nonDerivative · entry 2 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,295 F1 · kind: The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person. F2 · balance_after: Includes 52,083 restricted stock units. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 17:37 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock | 7,402 | $10.05 | $74,390.10 |
DisclosureSEC source: 0001567619-21-002141 · doc1.xml · nonDerivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes 52,083 restricted stock units. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 16:15 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0001567619-21-001600 · doc1.xml · derivative · entry 4 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,569 Underlying: Common Stock · 40,000 shares Expires 2028-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 16:15 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock | 6,144 | $19.00 | $116,736.00 |
DisclosureSEC source: 0001567619-21-001600 · doc1.xml · nonDerivative · entry 3 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,295 F1 · kind: The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person. F2 · balance_after: Includes 52,083 restricted stock units. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 16:15 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock | 40,000 | $20.10 | $804,000.00 |
DisclosureSEC source: 0001567619-21-001600 · doc1.xml · nonDerivative · entry 2 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,439 F1 · kind: The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person. F2 · balance_after: Includes 52,083 restricted stock units. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 16:15 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock | 40,000 | $10.05 | $402,000.00 |
DisclosureSEC source: 0001567619-21-001600 · doc1.xml · nonDerivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,439 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes 52,083 restricted stock units. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 16:23 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $17.58 | $0.00 |
DisclosureSEC source: 0001567619-21-000982 · doc1.xml · derivative · entry 2 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2031-01-11 F3 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 11, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 16:23 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantCommon Stock | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-000982 · doc1.xml · nonDerivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,439 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3 of the RSUs vest annually on January 11 of each year, with the first 1/3 vesting on January 11, 2022 and with the RSUs being fully vested on January 11, 2024, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. F2 · balance_after: Includes 52,083 RSUs. Read SEC document |
| January 10, 2021 Filed Jan 12, 2021 16:55 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Tax withholdingCommon Stock | 4,080 | $18.18 | $74,174.40 |
DisclosureSEC source: 0001567619-21-000922 · doc1.xml · nonDerivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,189 F1 · balance_after: Includes 20,833 restricted stock units. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 16:16 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0001567619-20-020095 · doc1.xml · derivative · entry 3 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,241 Underlying: Common Stock · 1,500 shares Expires 2024-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: All of the shares underlying this option are vested and exercisable as of the date hereof. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 16:16 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock, $0.0001 par value | 1,500 | $13.50 | $20,250.00 |
DisclosureSEC source: 0001567619-20-020095 · doc1.xml · nonDerivative · entry 2 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,269 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · balance_after: Includes 31,250 restricted stock units. F4 · balance_after: Includes 341 shares acquired on November 13, 2020, pursuant to Issuer's employee stock purchase plan. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 16:16 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 1,995 | $17.49 | $34,896.34 |
DisclosureSEC source: 0001567619-20-020095 · doc1.xml · nonDerivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,769 F1 · kind: The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $17.27 to $17.85, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: Includes 31,250 restricted stock units. F4 · balance_after: Includes 341 shares acquired on November 13, 2020, pursuant to Issuer's employee stock purchase plan. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 16:19 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 6,144 | $19.00 | $116,736.00 |
DisclosureSEC source: 0001567619-20-017922 · doc1.xml · nonDerivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,423 F1 · kind: The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person. F2 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| May 20, 2020 Filed May 22, 2020 16:30 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 1,278 | $17.66 | $22,569.48 |
DisclosureSEC source: 0001567619-20-011016 · doc1.xml · nonDerivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,567 F1 · kind: The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person. F2 · balance_after: Includes 31,250 restricted stock units. F3 · balance_after: Includes 1,004 shares acquired on May 15, 2020, pursuant to Issuer's employee stock purchase plan. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 18:16 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,159 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0001567619-20-004636 · doc1.xml · derivative · entry 3 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,569 Underlying: Common Stock · 3,159 shares Expires 2028-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 18:16 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 3,159 | $22.33 | $70,551.84 |
DisclosureSEC source: 0001567619-20-004636 · doc1.xml · nonDerivative · entry 2 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,841 F2 · kind: The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $22.09 to $22.73, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 18:16 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock, $0.0001 par value | 3,159 | $10.05 | $31,747.95 |
DisclosureSEC source: 0001567619-20-004636 · doc1.xml · nonDerivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 16:11 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,318 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0001567619-20-001235 · doc1.xml · derivative · entry 4 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,728 Underlying: Common Stock · 6,318 shares Expires 2028-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 16:11 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 2,798 | $20.08 | $56,185.80 |
DisclosureSEC source: 0001567619-20-001235 · doc1.xml · nonDerivative · entry 3 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,841 F2 · kind: The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $20.00 to $20.36, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 16:11 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 3,520 | $19.67 | $69,238.05 |
DisclosureSEC source: 0001567619-20-001235 · doc1.xml · nonDerivative · entry 2 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,639 F2 · kind: The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $19.00 to $19.98, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 16:11 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock, $0.0001 par value | 6,318 | $10.05 | $63,495.90 |
DisclosureSEC source: 0001567619-20-001235 · doc1.xml · nonDerivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 31,250 restricted stock units. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 17:48 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $17.73 | $0.00 |
DisclosureSEC source: 0001567619-20-001039 · doc1.xml · derivative · entry 4 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2030-01-10 F3 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 10, 2020, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 17:48 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantCommon Stock, $0.0001 par value | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-001039 · doc1.xml · nonDerivative · entry 3 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,841 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3 of the RSUs vest annually on January 10 of each year, with the first 1/3 vesting on January 10, 2021 and with the RSUs being fully vested on January 10, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. F2 · balance_after: Includes 31,250 RSUs. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 17:48 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Tax withholdingCommon Stock, $0.0001 par value | 7,077 | $17.73 | $125,475.21 |
DisclosureSEC source: 0001567619-20-001039 · doc1.xml · nonDerivative · entry 2 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,591 Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 17:48 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantCommon Stock, $0.0001 par value | 19,365 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-001039 · doc1.xml · nonDerivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,668 Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 16:09 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,159 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0001567619-19-022077 · doc1.xml · derivative · entry 3 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,046 Underlying: Common Stock · 3,159 shares Expires 2028-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 16:09 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 3,159 | $19.59 | $61,871.86 |
DisclosureSEC source: 0001567619-19-022077 · doc1.xml · nonDerivative · entry 2 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,303 F1 · kind: The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $19.085 to $19.98, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 16:09 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock, $0.0001 par value | 3,159 | $10.05 | $31,747.95 |
DisclosureSEC source: 0001567619-19-022077 · doc1.xml · nonDerivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2019 Filed Nov 20, 2019 16:22 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 3,112 | $18.88 | $58,757.36 |
DisclosureSEC source: 0001567619-19-021956 · doc1.xml · nonDerivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,303 F1 · kind: The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $18.74 to $19.065, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: Includes 30 shares acquired on November 15, 2019 pursuant to Issuer's employee stock purchase plan. Read SEC document |
| October 18, 2019 Filed Oct 22, 2019 16:06 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 1,388 | $19.02 | $26,399.76 |
DisclosureSEC source: 0000899243-19-025822 · doc4.xml · nonDerivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,385 F1 · kind: The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,159 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0000899243-19-025758 · doc4.xml · derivative · entry 3 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,205 Underlying: Common Stock · 3,159 shares Expires 2028-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 3,159 | $19.00 | $60,021.00 |
DisclosureSEC source: 0000899243-19-025758 · doc4.xml · nonDerivative · entry 2 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,773 F1 · kind: The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock, $0.0001 par value | 3,159 | $10.05 | $31,747.95 |
DisclosureSEC source: 0000899243-19-025758 · doc4.xml · nonDerivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,932 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 23, 2019 Filed Sep 25, 2019 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 740 | $21.78 | $16,117.20 |
DisclosureSEC source: 0000899243-19-024242 · doc4.xml · nonDerivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,773 F1 · kind: The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,159 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0000899243-19-023989 · doc4.xml · derivative · entry 3 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,364 Underlying: Common Stock · 3,159 shares Expires 2028-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 3,159 | $20.44 | $64,559.85 |
DisclosureSEC source: 0000899243-19-023989 · doc4.xml · nonDerivative · entry 2 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,513 F1 · kind: The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $19.94 to $20.725, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock, $0.0001 par value | 3,159 | $10.05 | $31,747.95 |
DisclosureSEC source: 0000899243-19-023989 · doc4.xml · nonDerivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,672 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2019 Filed Aug 23, 2019 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,318 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0000899243-19-022360 · doc4.xml · derivative · entry 4 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,523 Underlying: Common Stock · 6,318 shares Expires 2028-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| August 21, 2019 Filed Aug 23, 2019 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 6,058 | $21.75 | $131,765.74 |
DisclosureSEC source: 0000899243-19-022360 · doc4.xml · nonDerivative · entry 3 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,513 F1 · kind: The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $21.35 to $22.28, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 21, 2019 Filed Aug 23, 2019 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 260 | $20.73 | $5,388.68 |
DisclosureSEC source: 0000899243-19-022360 · doc4.xml · nonDerivative · entry 2 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,571 F1 · kind: The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $20.32 to $21.32, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 21, 2019 Filed Aug 23, 2019 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock, $0.0001 par value | 6,318 | $10.05 | $63,495.90 |
DisclosureSEC source: 0000899243-19-022360 · doc4.xml · nonDerivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,831 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 3,000 | $19.04 | $57,120.00 |
DisclosureSEC source: 0000899243-19-022200 · doc4.xml · nonDerivative · entry 1 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,513 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person. Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,159 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0000899243-19-017621 · doc4.xml · derivative · entry 6 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,841 Underlying: Common Stock · 3,159 shares Expires 2028-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 100 | $20.81 | $2,081.00 |
DisclosureSEC source: 0000899243-19-017621 · doc4.xml · nonDerivative · entry 5 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,513 F1 · kind: The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person. Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 16:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 3,059 | $20.32 | $62,166.22 |
DisclosureSEC source: 0000899243-19-017621 · doc4.xml · nonDerivative · entry 4 Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,613 F1 · kind: The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $19.75 to $20.75, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.